Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

Bausch Health Companies Inc., together with its subsidiaries, develops, manufactures, and markets a range of pharmaceutical, medical device, and over-the-counter (OTC) products primarily in the therapeutic areas of eye health, gastroenterology, and dermatology. The company operates through five segments: Bausch + Lomb, Salix, International Rx, Ortho Dermatologics, and Diversified Products. The Bausch + Lomb segment offers products with a focus on the vision care, surgical, and consumer, surgical, and ophthalmic pharmaceuticals products. The Salix segment provides gastroenterology products in the United States. The International Rx segment offers Solta products, branded and generic pharmaceutical products, OTC products, and medical device products, and Bausch + Lomb products in Canada, Europe, Asia, Australia, Latin America, Africa, and the Middle East. The Ortho Dermatologics segment provides dermatological products in the United States; and Solta medical aesthetic devices internationally. The Diversified Products segment offers pharmaceutical products in the areas of neurology and other therapeutic classes, as well as generic and dentistry products in the United States. The company was formerly known as Valeant Pharmaceuticals International, Inc. and changed its name to Bausch Health Companies Inc. in July 2018. Bausch Health Companies Inc. is headquartered in Laval, Canada.

Bausch Health Companies Inc.

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

FOR THE SIXTH CONSECUTIVE YEAR, 10 STUDENTS WITH GASTROINTESTINAL DISEASE WILL EACH RECEIVE A $10,000 SCHOLARSHIP  LAVAL, QC / ACCESS NEWSWIRE / AUGUST 7, 2025 / BAUSCH HEALTH COMPANIES INC. (NYSE:BHC)(TSX:BHC) AND ITS GASTROENTEROLOGY (GI) BUSINESS, SALIX PHARMACEUTICALS ("SALIX"), TODAY ANNOUNCED THE RECIPIENTS OF ITS 2025 SALIX GASTROINTESTINAL HEALTH SCHOLARS PROGRAM. FOR THE SIXTH YEAR, BAUSCH HEALTH IS PROUD TO AWARD 10 DESERVING STUDENTS LIVING WITH A GI DISEASE $10,000 EACH TO FURTHER THEIR HIGHER EDUCATION.

BAUSCH HEALTH ANNOUNCES 2025 GASTROINTESTINAL HEALTH SCHOLARS PROGRAM WINNERS

SECOND QUARTER CONSOLIDATED REVENUES OF $2.53 BILLION, UP 5% ON A REPORTED BASIS AND 4% ON AN ORGANIC (NON-GAAP)1 BASIS OVER THE PRIOR YEAR PERIOD GAAP NET INCOME ATTRIBUTABLE TO BAUSCH HEALTH COMPANIES OF $148 MILLION AND GAAP NET INCOME OF $128 MILLION CONSOLIDATED ADJUSTED EBITDA ATTRIBUTABLE TO BAUSCH HEALTH COMPANIES (NON-GAAP)1 OF $842 MILLION, UP 6% ON A REPORTED BASIS OVER THE PRIOR YEAR PERIOD BAUSCH HEALTH EXCLUDING BAUSCH + LOMB SECOND QUARTER 2025 RESULTS DELIVERED NINTH CONSECUTIVE QUARTER OF YEAR-OVER-YEAR REVENUE AND ADJUSTED EBITDA (NON-GAAP)1 GROWTH, WITH 5% BOTH REPORTED AND ORGANIC (NON-GAAP)1 REVENUE GROWTH, AND 10% ADJUSTED EBITDA (NON-GAAP)1 GROWTH ANNOUNCED UPCOMING REPAYMENT OF APPROXIMATELY $900 MILLION DOLLARS OF DEBT USING CASH ON HAND AFTER QUARTER-END ENTERED INTO AN AGREEMENT TO ACQUIRE DURECT CORPORATION IN JULY, WHICH IF ALL CLOSING CONDITIONS ARE SATISFIED AND THE ACQUISITION CLOSES, WILL ENABLE BAUSCH HEALTH TO USE ITS HEPATOLOGY EXPERTISE TO SEEK TO GAIN APPROVALS AND COMMERCIALIZE DURECT'S MAIN TREATMENT FOR ALCOHOL-INDUCED HEPATITIS REAFFIRMING FULL-YEAR 2025 REVENUE, ADJUSTED EBITDA (NON-GAAP)1, AND ADJUSTED CASH FLOW FROM OPERATIONS (NON-GAAP)1 GUIDANCE LAVAL, QC / ACCESS NEWSWIRE / JULY 30, 2025 / BAUSCH HEALTH COMPANIES INC. (NYSE:BHC)(TSX:BHC) ("BAUSCH HEALTH" OR THE "COMPANY" OR "WE" OR "OUR") TODAY ANNOUNCED ITS SECOND QUARTER 2025 FINANCIAL RESULTS AND OTHER KEY UPDATES FROM THE QUARTER. "IN THE SECOND QUARTER, WE ACHIEVED OUR NINTH CONSECUTIVE QUARTER OF YEAR-OVER-YEAR GROWTH IN REVENUE AND ADJUSTED EBITDA FOR BAUSCH HEALTH, EXCLUDING BAUSCH + LOMB.

BAUSCH HEALTH ANNOUNCES SECOND QUARTER 2025 RESULTS

DURECT'S LEAD ASSET, LARSUCOSTEROL, IS AN EPIGENETIC MODULATOR WITH FDA BREAKTHROUGH THERAPY DESIGNATION POTENTIAL TO BE THE FIRST FDA-APPROVED THERAPEUTIC OPTION FOR THE TREATMENT OF PATIENTS WITH ALCOHOLIC HEPATITIS PROPOSED ACQUISITION STRENGTHENS BAUSCH HEALTH'S COMMITMENT TO HEPATOLOGY AND PATIENTS SUFFERING WITH LIVER DISEASE COMPLICATIONS GLOBALLY LAVAL, QC AND CUPERTINO, CA / ACCESS NEWSWIRE / JULY 29, 2025 / BAUSCH HEALTH COMPANIES INC. (NYSE:BHC)(TSX:BHC), A GLOBAL, DIVERSIFIED PHARMACEUTICAL COMPANY, AND DURECT CORPORATION (NASDAQ:DRRX) TODAY ANNOUNCED A DEFINITIVE AGREEMENT UNDER WHICH BAUSCH HEALTH WILL INDIRECTLY ACQUIRE DURECT CORPORATION, INCLUDING A NOVEL THERAPEUTIC MOLECULE, LARSUCOSTEROL, WHICH CAN HARNESS THE POWER OF EPIGENETIC MODULATION. LARSUCOSTEROL, AN ENDOGENOUS SULFATED OXYSTEROL AND AN EPIGENETIC MODULATOR, HAS DEMONSTRATED PROMISING RESULTS FOR THE TREATMENT OF ALCOHOLIC HEPATITIS (AH) IN PHASE 2 TRIALS.

BAUSCH HEALTH TO ACQUIRE DURECT CORPORATION, STRENGTHENING COMMITMENT TO DEVELOPING INNOVATIVE SOLUTIONS FOR PATIENTS WITH LIVER DISEASE

VAUGHAN, ONTARIO--(BUSINESS WIRE)--BAUSCH + LOMB CORPORATION (NYSE/TSX: BLCO), A LEADING GLOBAL EYE HEALTH COMPANY DEDICATED TO HELPING PEOPLE SEE BETTER TO LIVE BETTER, TODAY ANNOUNCED OPHTHALMOLOGY AND THERAPY HAS PUBLISHED RESULTS FROM A PHASE 3 STUDY WHICH ASSESSED THE EFFICACY AND SAFETY OF LUMIFY PRESERVATIVE FREE REDNESS RELIEVER EYE DROPS COMPARED TO LUMIFY REDNESS RELIEVER EYE DROPS FOR REDUCING OCULAR REDNESS. SINCE LAUNCHING IN 2018, LUMIFY HAS BEEN THE NO. 1 DOCTOR-RECOMMENDED REDN.

BAUSCH + LOMB ANNOUNCES PUBLICATION OF PHASE 3 DATA ON LUMIFY PRESERVATIVE FREE REDNESS RELIEVER EYE DROPS

LAVAL, QC / ACCESS NEWSWIRE / JULY 28, 2025 / BAUSCH HEALTH COMPANIES INC. (NYSE: BHC)(TSX: BHC) ("BAUSCH HEALTH" OR THE "COMPANY") TODAY ANNOUNCED THAT ITS SUBSIDIARY, BAUSCH HEALTH AMERICAS, INC., HAS ISSUED AN IRREVOCABLE NOTICE OF REDEMPTION PURSUANT TO WHICH IT WILL REDEEM APPROXIMATELY $602 MILLION OF AGGREGATE PRINCIPAL AMOUNT OF ITS OUTSTANDING 9.25% SENIOR NOTES DUE 2026, CUSIP NOS. 91911XAV6 AND U9098VAN2 (THE "NOTES"), USING CASH ON HAND.

BAUSCH HEALTH TO REDUCE DEBT BY APPROXIMATELY $900 MILLION USING CASH ON HAND

LAVAL, QC / ACCESS NEWSWIRE / JULY 24, 2025 / BAUSCH HEALTH COMPANIES INC. (NYSE:BHC)(TSX:BHC), A GLOBAL, DIVERSIFIED PHARMACEUTICAL COMPANY, TODAY ANNOUNCED THE APPOINTMENT OF MICHAEL GOETTLER AND SANDRA LEUNG TO ITS BOARD OF DIRECTORS, EFFECTIVE JULY 22, 2025. THE APPOINTMENTS INCREASE THE SIZE OF THE BOARD FROM TEN TO TWELVE MEMBERS.

BAUSCH HEALTH ANNOUNCES THE APPOINTMENT OF TWO NEW MEMBERS TO ITS BOARD OF DIRECTORS

THIS PRESS RELEASE UPDATES THE HEADLINE OF THE PREVIOUSLY POSTED RELEASE LAVAL, QC / ACCESS NEWSWIRE / JULY 10, 2025 / BAUSCH HEALTH, CANADA INC., PART OF BAUSCH HEALTH COMPANIES INC. (NYSE:BHC)(TSX:BHC), TODAY ANNOUNCED THAT PRCABTREOTM (CLINDAMYCIN PHOSPHATE, ADAPALENE AND BENZOYL PEROXIDE) GEL 1.2% W/W, 0.15% W/W AND 3.1% W/W, FOR THE TREATMENT OF ACNE VULGARIS,1 IS NOW AVAILABLE TO BENEFICIARIES OF THE PUBLIC DRUG PLANS OF ONTARIO AND NOVA SCOTIA AS WELL AS THROUGH THE FEDERAL GOVERNMENT'S NON-INSURED HEALTH BENEFITS (NIHB) DRUG PLAN FOR INDIGENOUS POPULATIONS AND THAT OF THE CORRECTIONAL SERVICE OF CANADA (CSC). CABTREO IS A NEW TRIPLE-COMBINATION TOPICAL PRESCRIPTION TREATMENT FOR ACNE VULGARIS IN PATIENTS 12 YEARS OF AGE AND OLDER.

CORRECTING AND REPLACING: BAUSCH HEALTH, CANADA INC. TREATMENT FOR ACNE VULGARIS, (PR)CABTREO(TM) (CLINDAMYCIN PHOSPHATE, ADAPALENE AND BENZOYL PEROXIDE GEL), NOW AVAILABLE THROUGH PUBLIC DRUG PLANS OF ONTARIO, NOVA SCOTIA AND TWO FEDERAL PROGRAMS

LAVAL, QC / ACCESS NEWSWIRE / JULY 10, 2025 / BAUSCH HEALTH COMPANIES INC. (NYSE:BHC)(TSX:BHC), A GLOBAL, DIVERSIFIED PHARMACEUTICAL COMPANY, TODAY ANNOUNCED THE APPOINTMENT OF STEVEN LEE AS SENIOR VICE PRESIDENT, CONTROLLER AND CHIEF ACCOUNTING OFFICER, EFFECTIVE MONDAY, JULY 14. STEVEN BRINGS EXTENSIVE EXPERIENCE IN FINANCIAL TRANSFORMATION, MERGERS AND ACQUISITIONS, AND OPERATIONAL EXECUTION.

BAUSCH HEALTH APPOINTS NEW CHIEF ACCOUNTING OFFICER

LAVAL, QC / ACCESS NEWSWIRE / JULY 9, 2025 / BAUSCH HEALTH, CANADA INC., PART OF BAUSCH HEALTH COMPANIES INC. (NYSE:BHC)(TSX:BHC), TODAY ANNOUNCED THAT PRCABTREOTM (CLINDAMYCIN PHOSPHATE, ADAPALENE AND BENZOYL PEROXIDE) GEL 1.2% W/W, 0.15% W/W AND 3.1% W/W, FOR THE TREATMENT OF ACNE VULGARIS,1 IS NOW AVAILABLE TO BENEFICIARIES OF THE PUBLIC DRUG PLANS OF ONTARIO AND NOVA SCOTIA AS WELL AS THROUGH THE FEDERAL GOVERNMENT'S NON-INSURED HEALTH BENEFITS (NIHB) DRUG PLAN FOR INDIGENOUS POPULATIONS AND THAT OF THE CORRECTIONAL SERVICE OF CANADA (CSC). CABTREO IS A NEW TRIPLE-COMBINATION TOPICAL PRESCRIPTION TREATMENT FOR ACNE VULGARIS IN PATIENTS 12 YEARS OF AGE AND OLDER.

BAUSCH HEALTH, CANADA INC. TREATMENT FOR ACNE VULGARIS, (PR)CABTREO(TM) (CLINDAMYCIN PHOSPHATE, ADAPALENE AND BENZOYL PEROXIDE GEL), NOW AVAILABLE THROUGH PUBLIC DRUG PLANS OF ONTARIO, QUEBEC AND TWO FEDERAL PROGRAMS

FOCUSED ON HIGHLIGHTING REAL PATIENT EXPERIENCES, SALIX CONTINUES TO LEAD THE CHARGE IN EDUCATING AND ADVOCATING FOR THE HEPATIC ENCEPHALOPATHY COMMUNITY LAVAL, QC / ACCESS NEWSWIRE / JULY 7, 2025 / BAUSCH HEALTH COMPANIES INC. (NYSE:BHC)(TSX:BHC) AND ITS GASTROENTEROLOGY (GI) BUSINESS, SALIX PHARMACEUTICALS ("SALIX"), TODAY ANNOUNCED ITS NEW DIRECT-TO-CONSUMER (DTC) "I WISH I KNEW" CAMPAIGN FOR XIFAXAN (RIFAXIMIN), THE FIRST AND ONLY MEDICINE FDA APPROVED FOR THE REDUCTION IN RISK OF OVERT HEPATIC ENCEPHALOPATHY (OHE) RECURRENCE IN ADULTS. DESIGNED TO RAISE AWARENESS ABOUT OHE AND THE ROLE OF XIFAXAN, "I WISH I KNEW" SEEKS TO EDUCATE AND EMPOWER PATIENTS AND CAREGIVERS TO TAKE PROACTIVE STEPS IN MANAGING THEIR LIVER DISEASE.

BAUSCH HEALTH'S GASTROENTEROLOGY BUSINESS, SALIX PHARMACEUTICALS, LAUNCHES FRESH "I WISH I KNEW" CAMPAIGN TO EDUCATE PEOPLE ABOUT XIFAXAN(R) (RIFAXIMIN) FOR ADULTS AT RISK OF OVERT HEPATIC ENCEPHALOPATHY RECURRENCE

Bausch Health Companies Inc.

BHC

Price

Financials Overview

Financial Reports

No items found.

Press Releases

Bausch Health Companies Inc.

BHC.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financials Overview

Financial Reports

No items found.

Press Releases

BHC